J.P. Morgan Maintains Their Buy Rating on SAGE Therapeutics (SAGE)

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on SAGE Therapeutics (SAGE) on January 12. The company’s shares closed last Thursday at $96.83.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.9% and a 57.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $87.73, implying a -9.3% downside from current levels. In a report issued on January 4, Guggenheim also upgraded the stock to Buy with a $110.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $92.49 and a one-year low of $25.01. Currently, SAGE Therapeutics has an average volume of 704K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts